Expert Delphi survey on research and development into drugs for neglected diseases

Fehr A, Thuermann P, Razum O (2011)
BMC Health Services Research 11(1): 312.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ;
Abstract / Bemerkung
Background: Tropical infectious diseases are called neglected, because they are, inter alia, characterized by an R&D deficit. A similar deficit exists for rare (orphan) diseases which neither promise a sufficient return on R&D investment. To encourage the development of treatments for rare diseases, orphan drug acts were created which contain financial and non-financial incentives for the pharmaceutical industry. Similar instruments aimed exclusively at neglected diseases do not yet exist. Proposals for a regulatory approach to promote R&D for neglected diseases include the application of selected orphan drug incentives, or the implementation of a Medical Research and Development Treaty (MRDT) with national funding obligations for medical R&D. We compiled and analyzed experts' opinions on causes for the treatment deficit for neglected diseases and on desirable and feasible measures to promote neglected disease R&D. Hereby, the focus was on mechanisms contained in orphan drug regulations and in the Medical Research and Development Treaty draft (Discussion draft 4, 2005). Lastly, we solicited experts' opinions on the desirability and feasibility of a regulatory instrument to foster R&D for neglected diseases. Methods: An international online-Delphi survey was conducted with 117 (first round) and 56 (second round) experts of different professional backgrounds and professional affiliations who formulated and ranked causes and solutions related to the treatment deficit for neglected diseases. Results: In both rounds of survey, the majority of the participating experts (88.4% first round, 86.8% second round) advocated the development of a regulatory instrument to promote R&D for neglected diseases. Most experts (77.9% first round, 79.3% second round) also considered this to be a feasible option. With the exception of market exclusivity, which was viewed critically, key provisions contained in orphan drug regulations were judged favorably also for neglected diseases. A majority (87.1% first round, 77.2% second round) supported national funding obligations for neglected diseases which are proposed by the Medical Research and Development Treaty draft. Conclusions: While not all features of orphan drug regulations and of the MRDT draft received equal support, the view was expressed that a regulatory instrument would be a desirable and feasible measure to promote R&D for neglected diseases.
Erscheinungsjahr
Zeitschriftentitel
BMC Health Services Research
Band
11
Zeitschriftennummer
1
Seite
312
ISSN
PUB-ID

Zitieren

Fehr A, Thuermann P, Razum O. Expert Delphi survey on research and development into drugs for neglected diseases. BMC Health Services Research. 2011;11(1):312.
Fehr, A., Thuermann, P., & Razum, O. (2011). Expert Delphi survey on research and development into drugs for neglected diseases. BMC Health Services Research, 11(1), 312. doi:10.1186/1472-6963-11-312
Fehr, A., Thuermann, P., and Razum, O. (2011). Expert Delphi survey on research and development into drugs for neglected diseases. BMC Health Services Research 11, 312.
Fehr, A., Thuermann, P., & Razum, O., 2011. Expert Delphi survey on research and development into drugs for neglected diseases. BMC Health Services Research, 11(1), p 312.
A. Fehr, P. Thuermann, and O. Razum, “Expert Delphi survey on research and development into drugs for neglected diseases”, BMC Health Services Research, vol. 11, 2011, pp. 312.
Fehr, A., Thuermann, P., Razum, O.: Expert Delphi survey on research and development into drugs for neglected diseases. BMC Health Services Research. 11, 312 (2011).
Fehr, Angela, Thuermann, Petra, and Razum, Oliver. “Expert Delphi survey on research and development into drugs for neglected diseases”. BMC Health Services Research 11.1 (2011): 312.

7 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

A Delphi study and ranking exercise to support commissioning services: future delivery of Thrombectomy services in England.
Halvorsrud K, Flynn D, Ford GA, McMeekin P, Bhalla A, Balami J, Craig D, White P., BMC Health Serv Res 18(1), 2018
PMID: 29471828
The use of ovarian reserve markers in IVF clinical practice: a national consensus.
La Marca A, Ferraretti AP, Palermo R, Ubaldi FM., Gynecol Endocrinol 32(1), 2016
PMID: 26531067
KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting.
Barone C, Pinto C, Normanno N, Capussotti L, Cognetti F, Falcone A, Mantovani L., PLoS One 9(1), 2014
PMID: 24465771

45 References

Daten bereitgestellt von Europe PubMed Central.

Neglected tropical diseases: equity and social determinants
AUTHOR UNKNOWN, 2010
Integrated control of the neglected tropical diseases. A neglected opportunity ripe for action
AUTHOR UNKNOWN, 2008
Working to overcome the global impact of neglected tropical diseases
AUTHOR UNKNOWN, 2010
Neglected Disease Research & Development: New Times, New Trends
AUTHOR UNKNOWN, 2009
Drugs for neglected diseases: a failure of the market and a public health failure?
Trouiller P, Torreele E, Olliaro P, White N, Foster S, Wirth D, Pecoul B., Trop. Med. Int. Health 6(11), 2001
PMID: 11703850
Neglected disease research and development: how much are we really spending?
Moran M, Guzman J, Ropars AL, McDonald A, Jameson N, Omune B, Ryan S, Wu L., PLoS Med. 6(2), 2009
PMID: 19192946
Spurring new research for neglected diseases.
Anderson GF., Health Aff (Millwood) 28(6), 2009
PMID: 19887416
Patent sense.
Herrling P., Nature 449(7159), 2007
PMID: 17851514
Mission possible.
Hopkins AL, Witty MJ, Nwaka S., Nature 449(7159), 2007
PMID: 17851512
G-Finder 2010. Global Funding of Innovation for Neglected Diseases. Neglected disease research and development: Is the Global Financial Crisis Changing R&D?
AUTHOR UNKNOWN, 2011
Neglected Tropical Diseases. Hidden successes, Emerging Opportunities
AUTHOR UNKNOWN, 2006
Drug development for neglected diseases: a deficient market and a public-health policy failure.
Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N., Lancet 359(9324), 2002
PMID: 12090998
Networking for rare diseases: a necessity for Europe
AUTHOR UNKNOWN, 2007
Policies for Orphan Diseases and Orphan Drugs. Health Technology Assessment (HTA)
AUTHOR UNKNOWN, 2009
Two decades of orphan product development.
Haffner ME, Whitley J, Moses M., Nat Rev Drug Discov 1(10), 2002
PMID: 12360259
[Rare diseases. Funding programs in Germany and Europe].
Wetterauer B, Schuster R., Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 51(5), 2008
PMID: 18425694
Interagency Task Force Report on Significant Drugs of Limited Commercial Value
AUTHOR UNKNOWN, 1979
Orphan Drug Laws in Europe and the US: Incentives for the Research and Development of Medicines for the Diseases of Poverty
AUTHOR UNKNOWN, 2001
The Orphan Drug Act (as amended)
AUTHOR UNKNOWN, 1983

AUTHOR UNKNOWN, 2010
Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts.
Trouiller P, Battistella C, Pinel J, Pecoul B., Trop. Med. Int. Health 4(6), 1999
PMID: 10444316
Orphan drug legislation: lessons for neglected tropical diseases.
Villa S, Compagni A, Reich MR., Int J Health Plann Manage 24(1), 2009
PMID: 18435430
Public health, innovation and intellectual property rights
AUTHOR UNKNOWN, 2006
Medical Research and Development Treaty (MRDT)
AUTHOR UNKNOWN, 2005
Research and Development. Coordination and Financing
AUTHOR UNKNOWN, 2010
The Policy Delphi
AUTHOR UNKNOWN, 2002
Globalpark Enterprise Feedback Suite 5.2
AUTHOR UNKNOWN, 2007
Zielgeführte Evaluation von Programmen - ein Leitfaden
AUTHOR UNKNOWN, 2000

AUTHOR UNKNOWN, 2002
Government-Controlled Pharmaceutical Research and Development: A Recipe for Desaster
AUTHOR UNKNOWN, 2006
Increasing R&D incentives for neglected diseases: Lessons from the Orphan Drug Act
AUTHOR UNKNOWN, 2005
Editorial: drug development for neglected diseases: a public health challenge.
Fehr A, Thurmann P, Razum O., Trop. Med. Int. Health 11(9), 2006
PMID: 16930253
Macroeconomics and Health: Investing in Health for Economic Development
AUTHOR UNKNOWN, 2001
Global strategy and plan of action on public health, innovation and intellectual property
AUTHOR UNKNOWN, 2008
Proposal by Bangladesh, Barbados, Bolivia and Suriname
AUTHOR UNKNOWN, 2009
Patens and R&D Incentives: comments on the Hubbard and Love Trade Framework for Financing Pharmaceutical R&D
AUTHOR UNKNOWN, 2004
A Global Medical Research and Development Treaty. An answer to global health needs?
AUTHOR UNKNOWN, 2007
A new trade framework for global healthcare R&D.
Hubbard T, Love J., PLoS Biol. 2(2), 2004
PMID: 14966544
Reply to the comments requested by CIPIH and WHO to the CPTech proposal for a Medical Research and Development Treaty (MRDT)
AUTHOR UNKNOWN, 2005
Review of CPTech Proposal for an R&D Treaty
AUTHOR UNKNOWN, 2005
Expanding global research and development for neglected diseases.
Winters DJ., Bull. World Health Organ. 84(5), 2006
PMID: 16710555

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 22087801
PubMed | Europe PMC

Suchen in

Google Scholar